GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » PEG Ratio

Akari Therapeutics (FRA:CLA) PEG Ratio : 0.00 (As of Sep. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Akari Therapeutics's PE Ratio without NRI is 0.00. Akari Therapeutics's 5-Year EBITDA growth rate is 33.00%. Therefore, Akari Therapeutics's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Akari Therapeutics's PEG Ratio or its related term are showing as below:



FRA:CLA's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.62
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Akari Therapeutics PEG Ratio Historical Data

The historical data trend for Akari Therapeutics's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics PEG Ratio Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akari Therapeutics's PEG Ratio

For the Biotechnology subindustry, Akari Therapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's PEG Ratio falls into.



Akari Therapeutics PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Akari Therapeutics's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/33.00
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Akari Therapeutics  (FRA:CLA) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Akari Therapeutics PEG Ratio Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics Business Description

Traded in Other Exchanges
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.

Akari Therapeutics Headlines

From GuruFocus

Ouster to Host Virtual Investor Day on February 22, 2021

By Business Wire Business Wire 02-16-2021

Ouster Signs Multi-Year Supply Agreement with Lux Modus

By Business Wire Business Wire 02-03-2021

Ouster to Present at Upcoming Investor Conferences

By Business Wire Business Wire 03-01-2021